Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001737287-25-000042 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-18 | 2025-03-14 | ALLO | Chang David D | Pres, CEO, Dir | S - Sale | $1.96 | -46.7K | 5.28M | -0.9% | -$91.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | S | D | 46,668 | $1.96 | 5,276,569 | D | — | — | (F1) Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at a single price point of $1.96. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price set forth above. (F3) Includes 6000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program. |